Wachiwit
- BioVie (NASDAQ:BIVI) said the FDA has approved its application to initiate a Phase 2 study of its drug bezisterim in the treatment of neurological symptoms associated with long COVID.
- The FDA authorization puts the company ahead of schedule. It also makes it eligible to receive an additional $12.6M in grant funding from the U.S. Department of Defense, according to a company statement.
